Compounds, methods of screening, and in vitro and in vivo...

Details Compounds, methods of screening, and in vitro and in vivo... Compounds, methods of screening, and in vitro and in vivo...

2005-04-13

2008-11-11

Mosher, Mary E (Department: 1648)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S023720, C536S024500

Reexamination Certificate

active

07449450

ABSTRACT:
Novel polypeptides having anti-apoptotic activity, and methods of screening for such novel polypeptides having anti-apoptotic activity, and polynucleotides encoding such polypeptides; Compounds that regulate or modulate apoptosis and/or anti-apoptotic activity, such as compounds having anti-apoptotic activity, and such as compounds that induce, restore, or modulate apoptosis and/or inhibit, diminish, or modulate anti-apoptotic activity, methods of screening for such compounds, and methods of using such compounds in the therapeutic treatment of diseases; Methods of treating eukaryotic cells with compounds that regulate or modulate apoptosis and/or anti-apoptotic activity; Methods of enhancing the stability, growth, and/or productivity of eukaryotic cells; Pharmaceutical compositions that regulate or modulate apoptosis and/or anti-apoptotic activity.

REFERENCES:
patent: 6204251 (2001-03-01), Cuthbertson
Cinatl et al., “Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells,” Intervirology. 1996;39(4):259-69.
Cinatl et al., “Persistent Human Cytomegalovirus Infection Induces Drug Resistance and Alteration of Programmed Cell Death in Human Neuroblastoma Cells,” Cancer Research, 58, pp. 367-372 (1998).
Azad et al., “Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs,” Antiviral Res. Oct. 1995;28(2):101-11.
Crooke, “Antisense therapeutics,” Biotechnol Genet Eng Rev. 1998;15:121-57.
Mulamba et al., “Human Cytomegalovirus Mutant with Sequence-Dependent Resistance to the Phosphorothioate Oligonucleotide Fomivirsen (ISIS 2922),” Antimicrobial Agents and Chemotherapy, vol. 42, No. 4, pp. 971-973 (1998).
Leeds et al., “Pharmacokinetics of a Potential Human Cytomegalovirus Therapeutic, A Phosphorothioate Oligonucleotide, After Intravitreal Injection in the Rabbit,” Drug Metabolism and Disposition, vol. 25, No. 8, pp. 921-926 (1997).
Schleiss et al., “Progress toward an elusive goal: current status of cytomegalovirus vaccines,” Expert. Rev. Vaccines 4(3), 381-406 (2005).
Temsamani et al. “Antisense approach for the treatment of cytomegalovirus infection.” Expert Opinion on Investigational Drugs 6(6): 1157-1167, 1997.
Kronenwett et al. “Antisense strategies for the treatment of hematological malignancies and solid tumors.” Ann. Hematol. 77: 1-12, 1998.
Cinatl et al. “Modulatory effects of human cytomegalovirus infection on malignant properties of cancer cells.” intervirology 39(4): 259-269, 1996.
Pari et al,Antimicrobial Agents and Chemotherapy, 39(5):1157-1161 (1995).
Smith et al,J. of Virology, 69(3):1925-1931 (1995).

Affiliated with

Also associated with

Rating

Compounds, methods of screening, and in vitro and in vivo... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, methods of screening, and in vitro and in vivo..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, methods of screening, and in vitro and in vivo... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4020088